Condition: Multiple Myeloma · Hypogammaglobulinemia · Hypogammaglobulinemia, Acquired · Sponsor: Memorial Sloan Kettering Cancer Center
The main purpose of this study is to see if IgPro20 can prevent infection in people with multiple myeloma (MM) who have hypogammaglobulinemia from receiving bispecific monoclonal antibodies (BsAbs).
This description comes directly from the study's public registry record.
Zainab Shahid, MBBS · 212-639-6483 · shahidz@mskcc.org
Sergio Giralt, MD · 646-608-3731 · giralts@mskcc.org
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Basking Ridge (All Protocol Activities) | Basking Ridge, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Monmouth (All Protocol Activities) | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen (All Protocol Activities) | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Suffolk-Commack (All Protocol Activity) | Commack, New York, United States | Recruiting |
| Memorial Sloan Kettering Westchester (All Protocol Activities) | Harrison, New York, United States | Recruiting |
| Mount Sinai Hospital | New York, New York, United States | Not Yet Recruiting |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Nassau (All Protocol Activities) | Uniondale, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06976476